Full Description
As a general rule, for every 10,000 molecules screened in a given program in the laboratory, only one will survive to launch. To minimize costs, companies need to catch potential failures, due either to lack of clinical effect or toxicity, in the early discovery phase, long before they reach patients. Experimental Therapeutics introduces the dynamic and competitive discipline of experimental medicine. Informative, concise, and easy-to-read, the book emphasizes what scientists involved in drug discovery need to know about the rapid advances made in molecular biology, genetics, and technology. Each chapter starts with a summary box, has several high yield boxes, tables, and figures and ends with a reference section that has key URLs and carefully selected references to scientific papers. The book is a useful primer for anyone working to advance the pharmacological management of disease.
Contents
DRUG DISCOVERY AND DEVELOPMENTThe Clinical Pharmacologist's View: Drug Discovery and Early Developments, Sir Colin DolleryThe Toxicologist's View: Non-Clinical Safety Assessment, Anthony Lynch and John ConnellyThe Regulator's View: Regulatory Requirements for Marketing Authorizations for New Medicinal Products in the European Union, Rashmi R. Shah, Sarah K. Branch, and Christopher SteeleThe Use of Pharmacogenetics to Maximize Therapeutic Benefit, Andrew G. RenwickDrug Chirality: Pharmacology in Three Dimensions, Christian Meisel, Matthias Schwab, and Andrew J. HuttSurrogate Endpoints, James J. Oliver and David J. WebbPositron Emission Tomography (PET) as a Tool in Pharmacology: Examples from Neuroscience, Eugenii A. Rabiner and Paul M. GrasbyNOVEL THERAPIESTargeting Nuclear Receptors: PPARs as Targets for Drug Design, Colin N.A. Palmer and Martin R. WilkinsThe Use of Antisense Oligonucleotides as Therapeutic Agents, Punit RamrakhaGene Therapy: Theoretical and Practical Aspects, Rebecca Kristeleit and Martin R. WilkinsIndex
